61-Year-Old Male with Joint Stiffness

  • Kevin K. Wu
  • Michael P. Lee
  • Jashin J. Wu
Part of the Clinical Cases in Dermatology book series (CLIDADE)


Psoriatic arthritis (PsA) is a chronic, inflammatory, seronegative spondyloarthropathy associated with psoriasis. Symptoms of PsA improve with activity and include tenderness, stiffness, swelling, and reduced range of motion of the involved joints. If left untreated, PsA may lead to permanent joint damage. Biologics such as TNF inhibitors, IL-12/23 inhibitor, and IL-17 inhibitors are effective in both improving symptoms and inhibiting radiographic joint disease progression in PsA.


Psoriatic arthritis TNF inhibitors IL-17 inhibitors Ustekinumab Methotrexate Apremilast 


  1. 1.
    Gottlieb AB, Mease PJ, Mark Jackson J, Eisen D, Amy Xia H, Asare C, Stevens SR. Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists’ offices. J Dermatolog Treat. 2006;17(5):279–87. Scholar
  2. 2.
    Chang CA, Gottlieb AB, Lizzul PF. Management of psoriatic arthritis from the view of the dermatologist. Nat Rev Rheumatol. 2011;7(10):588–98. Scholar
  3. 3.
    Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2018;80:251–265.e19. Scholar
  4. 4.
    Cohen MR, Reda DJ, Clegg DO. Baseline relationships between psoriasis and psoriatic arthritis: analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies. J Rheumatol. 1999;26(8):1752–6.PubMedGoogle Scholar
  5. 5.
    Queiro R, Morante I, Cabezas I, Acasuso B. HLA-B27 and psoriatic disease: a modern view of an old relationship. Rheumatology (Oxford). 2016;55(2):221–9. Scholar
  6. 6.
    Helliwell P. Psoriasis and psoriatic arthritis: an integrated approach. Berlin: Springer; 2005.Google Scholar
  7. 7.
    Reich K, Kruger K, Mossner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009;160(5):1040–7. Scholar
  8. 8.
    Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl 2):ii14–7. Scholar
  9. 9.
    Brockbank JE, Stein M, Schentag CT, Gladman DD. Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis. 2005;64(2):188–90. Scholar
  10. 10.
    Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014;74(4):423–41. Scholar
  11. 11.
    Chou R, Helfand M, Peterson K, Dana T, Roberts C. Drug class review: cyclo-oxygenase (COX)-2 inhibitors and non-steroidal anti-inflammatory drugs (NSAIDs): final report update 3. Portland (OR); 2006.Google Scholar
  12. 12.
    Brodell RT, Williams L. A corticosteroid-induced flare of psoriasis. How to control or, better yet, avoid. Postgrad Med. 1999;106(7):31–2. Scholar
  13. 13.
    Mrowietz U, Domm S. Systemic steroids in the treatment of psoriasis: what is fact, what is fiction? J Eur Acad Dermatol Venereol. 2013;27(8):1022–5. Scholar
  14. 14.
    Coates LC, Gossec L, Ramiro S, Mease P, van der Heijde D, Smolen JS, et al. New GRAPPA and EULAR recommendations for the management of psoriatic arthritis. Rheumatology (Oxford). 2017;56(8):1251–3. Scholar
  15. 15.
    Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, et al. European League Against rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3):499–510. Scholar
  16. 16.
    Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, et al. European League Against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71(1):4–12. Scholar
  17. 17.
    Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68(9):1387–94. Scholar
  18. 18.
    Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52(10):3279–89. Scholar
  19. 19.
    Alwawi EA, Krulig E, Gordon KB. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know? Dermatol Ther. 2009;22(5):431–40. Scholar
  20. 20.
    Gniadecki R, Kragballe K, Dam TN, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol. 2011;164(5):1091–6. Scholar
  21. 21.
    Kavanaugh A, McInnes IB, Mease PJ, Hall S, Chinoy H, Kivitz AJ, et al. Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: results from the randomized placebo-controlled FUTURE 2 study. J Rheumatol. 2016;43(9):1713–7. Scholar
  22. 22.
    Kavanaugh A, Mease PJ, Reimold AM, Tahir H, Rech J, Hall S, et al. Secukinumab for long-term treatment of psoriatic arthritis: a two-year followup from a phase III, randomized, double-blind placebo-controlled Study. Arthritis Care Res (Hoboken). 2017;69(3):347–55. Scholar
  23. 23.
    Kavanaugh A, Ritchlin C, Rahman P, Puig L, Gottlieb AB, Li S, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014;73(6):1000–6. Scholar
  24. 24.
    Rahman P, Puig L, Gottlieb AB, Kavanaugh A, McInnes IB, Ritchlin C, et al. Ustekinumab treatment and improvement of physical function and health-related quality of life in patients with psoriatic arthritis. Arthritis Care Res (Hoboken). 2016;68(12):1812–22. Scholar
  25. 25.
    van der Heijde D, Gladman DD, Kishimoto M, Okada M, Rathmann SS, Moriarty SR, et al. Efficacy and safety of Ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III Study (SPIRIT-P1). J Rheumatol. 2018;45(3):367–77. Scholar
  26. 26.
    Combe B, Behrens F, McHugh N, Brock F, Kerkmann U, Kola B, Gallo G. Comparison of etanercept monotherapy and combination therapy with methotrexate in psoriatic arthritis: results from 2 clinical trials. J Rheumatol. 2016;43(6):1063–7. Scholar
  27. 27.
    Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, et al. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. J Rheumatol. 2015;42(3):479–88. Scholar
  28. 28.
    Salvarani C, Macchioni P, Olivieri I, Marchesoni A, Cutolo M, Ferraccioli G, et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol. 2001;28(10):2274–82.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Kevin K. Wu
    • 1
  • Michael P. Lee
    • 2
  • Jashin J. Wu
    • 3
  1. 1.Frank H. Netter MD School of Medicine at Quinnipiac UniversityNorth HavenUSA
  2. 2.Eastern Virginia Medical SchoolNorfolkUSA
  3. 3.Founder and CEODermatology Research and Education FoundationIrvineUSA

Personalised recommendations